An Association between Liver Markers and Physiological Variables: Comparison between Normal and Fatty Liver Subjects

  • Hyun, Kyung-Yae (Department of Clinical Labortory Science, College of Natural Sciences, Dong-Eui University)
  • Received : 2011.03.08
  • Accepted : 2011.05.26
  • Published : 2011.06.30

Abstract

We evaluated whether liver markers such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltranspeptidase (GGT), and bilirubin have a relationship with other physiological factors in the normal (n=115) and fatty liver subjects (n=122) and there are differences between the two populations. Body indices were higher in the fatty liver group than in the normal group. Liver markers and blood pressure (BP) were greater in the fatty liver group than in the normal group. AST and ALT levels were positively correlated with body indices in the fatty liver group, but not in the normal group. AST, ALT and GGT levels in the fatty liver group had positive relationship with cardiovascular indices (CI). ALP and bilirubin levels were negatively associated with some of CI. Liver markers were negatively or positively correlated with inflammatory markers, thyroid hormones, or several biochemical markers levels. These findings suggest that abnormal changes in liver markers may be useful tool for diagnosis or prognosis of development of cardiovascular and/or inflammatory diseases as well as metabolic syndrome.

Keywords

References

  1. Babali A, Cakal E, Purnak T, Bıyıkoglu I, Cakal B, Yuksel O, Koklu S. Serum alpha-fetoprotein levels in liver steatosis. Hepatol Int. 2009. (in press)
  2. Baou K, Vlachopoulos C, Manesis E, Archimandritis A, Stefanadis C. Non-alcoholic fatty liver and cardiovascular disease: an emerging relationship. Hellenic J Cardiol. 2007. 1: 37-41.
  3. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009. 7: 539-564.
  4. Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. N Engl J Med. 1966. 275: 457-464. https://doi.org/10.1056/NEJM196609012750902
  5. Choi SC, Cho BK, Lee YH, Chang KS. Preoperative levels of hematological and biochemical indices affect perioperative variables in adult patients with coronary artery bypass graft surgery. J Exp Bio Sci. 2010. 16: 150-158.
  6. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003. 98: 960-967. https://doi.org/10.1111/j.1572-0241.2003.07486.x
  7. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998. 27: 273-278. https://doi.org/10.1002/hep.510270140
  8. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007. 115: 2526-2532. https://doi.org/10.1161/CIRCULATIONAHA.106.657627
  9. Galvan AQ, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995. 268: E1-E5.
  10. Ghem CR, Sarmento-Leite E, de Quadros AS, Rossetto S, Gottschall CA. Serum bilirubin concentration in patients with an established coronary artery disease. Int Heart J. 2010. 51: 86-91. https://doi.org/10.1536/ihj.51.86
  11. Hillbom M, Saloheimo P, Juvela S. Alcohol consumption, blood pressure, and the risk of stroke. Curr Hypertens Rep. 2011 3: 208-213.
  12. Iacobellis G, Pellicelli AM, Grisorio B, Barbarini G, Leonetti F, Sharma AM, Barbaro G. Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat. Obesity. 2008. 16: 179-183. https://doi.org/10.1038/oby.2007.50
  13. Ji HF, Shen L. Uric acid potentially links fatty liver and high blood pressure. Hepatology. 2010 4: 1518-1519.
  14. Kim HC, Choi KS, Jang YH, Shin HW DJ, Kim ES. Normal serum aminotransferase levels and the metabolic syndrome: Korean National Health and Nutrition Examination Surveys. Yonsei Med J. 2006. 47: 542-550. https://doi.org/10.3349/ymj.2006.47.4.542
  15. Kshatriya S, Liu K, Salah A, Szombathy T, Freeman RH, Reams GP, Spear RM, Villarreal D. Obesity hypertension: the regulatory role of leptin. Int J Hypertens. 2011. 2011: 1-8.
  16. Liu MH, Yan M, Gao X, Gao J. Association of abnormality of liver enzymes and metabolic syndrome in patients with nonalcoholic fatty liver disease. Zhonghua Yi Xue Za Zhi. 2007. 87: 253-255.
  17. Martins MC, Faleiro LL, Afonso B, Fonseca A. Association of gamma glutamyltransferase, metabolic syndrome and cardiovascular risk. Acta Med Port. 2010. 23: 579-588.
  18. Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol. 2010. 13: 36-41. https://doi.org/10.1111/j.1751-7141.2009.00054.x
  19. Reaven GM. Role of insulin resistance in human disease. Banting Lecture. 1988. 37: 1595-1607.
  20. Samanc H, Stojic V, Kirovski D, Jovanovic M, Cernescu H, Vujanac I. Thyroid Hormones Concentrations during the Mid-Dry Period: An Early Indicator of Fatty Liver in Holstein-Friesian Dairy Cows. J Thyroid Res. 2010. 2010: 1-6.
  21. Schindhelm RK, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ, Diamant M. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med. 2007. 24: 430-435. https://doi.org/10.1111/j.1464-5491.2007.02100.x
  22. Sidorenkov O, Nilssen O, Grjibovski AM. Metabolic syndrome in Russian adults: associated factors and mortality from cardiovascular diseases and all causes. BMC Public Health. 2010. 10: 582-577. https://doi.org/10.1186/1471-2458-10-582
  23. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006. 47: 51-59. https://doi.org/10.1053/j.ajkd.2005.10.006
  24. Tagami T, Kimura H, Ohtani S, Tanaka T, Tanaka T, Hata S, Saito M, Miyazaki Y, Araki R, Tanaka M, Yonezawa K, Sawamura M, Ise T, Ogo A, Shimbo T, Shimatsu A, Naruse M. Multicenter study on the prevalence of hypothyroidism in patients with hypercholesterolemia. Endo Cr J. 2011. 10: 1-7.
  25. Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol. 2007. 27: 435-440. https://doi.org/10.1159/000105142
  26. Tuttle KR, Short RA, Johnson RJ. Sex differences in uric acid and risk factors for coronary artery disease. Am J Cardiol. 2001. 87: 1411-1414. https://doi.org/10.1016/S0002-9149(01)01566-1